COSCIENS Biopharma shares are trading lower after the company announced results from its Phase 3 DETECT-Trial of AEZS-130-P02. The primary endpoint was not met.
COSCIENS Biopharma shares are trading lower after the company announced results from its Phase 3 DETECT-Trial of AEZS-130-P02. The primary endpoint was not met.